Generics

NEW YORK — The global market for drug packaging is expected to experience tremendous growth over the next few years, according to a new report.

MALVERN, Pa. – A subsidiary of Endo Health Solutions is buying Boca Pharmacal for $225 million, Endo said Wednesday.

The Malvern, Pa.-based drug maker said the acquisition, through its Qualitest generics subsidiary, would give it access to a "unique" portfolio of generic drugs, an attractive pipeline and would build on Qualitest's strength in controlled substances. Boca focuses on niche areas, commercializing and developing drugs that include controlled substances, semisolids and solutions.

LAKE FOREST, Ill. — Akorn on Monday morning announced its proposed acquisition of Hi-Tech Pharmacal for $640 million in cash.

WASHINGTON — The National Council on Aging on Tuesday announced that actor Lee Majors is joining the Council's Flu + You program to help encourage seniors to get their annual flu shots. As a part of his involvement in the Flu + You campaign, Majors will appear in a public service announcement that follows him as he embarks on "an important and action-packed mission: learning about his vaccine options and getting vaccinated against the flu."

NEW YORK — Lawmakers in California have passed a bill that would restrict the use of follow-on versions of biotech drugs known as biosimilars, according to published reports.

NEW YORK — A new report by the American Academy of Pediatrics indicates that it is safe for women to take the medications and vaccinations they need while breast-feeding.

DEERFIELD, Ill. — Walgreens on Monday announced that this year's flu shots are now available at all Walgreens pharmacies, Healthcare Clinics at select Walgreens and Duane Reade pharmacies in New York. 

PITTSBURGH — The Food and Drug Administration has approved a supplemental regulatory application from Mylan for a generic antidepressant that was subject last year to scrutiny by the agency amid reports of efficacy problems, Mylan said Thursday.

The drug maker announced the approval of its supplemental abbreviated new drug application, or sANDA, for bupropion hydrochloride extended-release tablets in the 300-mg strength. The drug is a generic version of GlaxoSmithKline's Wellbutrin XL.